A Phase I Open Label Trial of a Combination of Nivolumab and Bevacizumab in Patients With Advanced and or Metastatic Hepatocellular Carcinoma
Phase of Trial: Phase I
Latest Information Update: 28 Jan 2019
At a glance
- Drugs Bevacizumab (Primary) ; Nivolumab (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- Acronyms NUANCE
- 11 Apr 2018 Status changed from not yet recruiting to recruiting.
- 04 Apr 2018 Planned initiation date changed from 1 Mar 2018 to 1 Apr 2018.
- 03 Jan 2018 New trial record